In the review ‘Is quetiapine a drug of abuse? Reexamining the issue of addiction’, published in the November 2008 issue of Expert Opinion on Drug Safety (Expert Opin. Drug Saf. (2008) 7(6):739-748), it has been brought to our attention that the disclosure statement was incomplete due to an editorial error. The author has advised that a full and transparent declaration be provided with regards to this manuscript.
Below is the complete declaration of interests:
Declaration of interests
Dr Oleg V Tcheremissine received research support from the following pharmaceutical companies and organizations: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Lundbeck, National Institute of Health/National Institute on Drug Abuse (NIDA), Novartis, sanofi-aventis and UBC. He is a member of Speakers Bureau and received honoraria from Abbott Laboratories, AstraZeneca Pharmaceuticals and Pfizer.
The editors and publisher sincerely regret any inconvenience this may have caused the author and our readers.